Author:
Dorman Susan E.,Nahid Payam,Kurbatova Ekaterina V.,Goldberg Stefan V.,Bozeman Lorna,Burman William J.,Chang Kwok-Chiu,Chen Michael,Cotton Mark,Dooley Kelly E.,Engle Melissa,Feng Pei-Jean,Fletcher Courtney V.,Ha Phan,Heilig Charles M.,Johnson John L.,Lessem Erica,Metchock Beverly,Miro Jose M.,Nhung Nguyen Viet,Pettit April C.,Phillips Patrick P.J.,Podany Anthony T.,Purfield Anne E.,Robergeau Kathleen,Samaneka Wadzanai,Scott Nigel A.,Sizemore Erin,Vernon Andrew,Weiner Marc,Swindells Susan,Chaisson Richard E.
Funder
Centers for Disease Control and Prevention
AIDS Clinical Trials Group
National Institutes of Health
U.S. Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Institute of Allergy and Infectious Diseases
Subject
Pharmacology (medical),General Medicine
Reference67 articles.
1. Geneva, Switzerland: World Health Organization; 2018. Report No.: 978–92–4-156564-6;World Health Organization. Global tuberculosis report,2018
2. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis;Nahid;Clin. Infect. Dis.,2016
3. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update;World Health Organization,2017
4. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications;Fox;Int. J. Tubercul. Lung Dis.,1999
5. Why do we use 600 mg of rifampicin in tuberculosis treatment?;van Ingen;Clin. Infect. Dis.,2011
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献